With today’s approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide Bexsero’s two-dose regimen offers a flexible dosing schedule, with the first and second doses administered at least … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Andrin Oswald, Bexsero®, FDA, meningococcal disease caused by meningitis B, Novartis
FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada Novartis is pursuing a US license that would allow immediate public health response to … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Switzerland
Tagged Andrin Oswald, bacterial infection, Bexsero®, Investigational New Drug (IND) designation, licensed broad coverage vaccine, Lynn Bozof, MenB, MenB outbreaks, meningococcal disease, Meningococcal Group B Vaccine, meningococcal serogroup B (MenB) vaccine, Novartis, Novartis Vaccines, protect against MenB, serogroup B, University of California Santa Barbara, US license for Bexsero, vaccination program
Novartis supplies MenB vaccine for a vaccination program at Princeton, following approvals by health authorities and University officials Bexsero, already licensed in Europe, Australia and Canada, is the only broad coverage vaccine to help protect against MenB disease MenB is … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?